Literature DB >> 21343550

Denosumab for prevention of skeletal-related events in patients with bone metastases from solid tumors: incremental benefit, debatable value.

Howard West.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21343550     DOI： 10.1200/JCO.2010.33.5596

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  4 in total

Review 1.  Pharmacoeconomics of bisphosphonates for skeletal-related event prevention in metastatic non-breast solid tumours.

Authors:  John A Carter; Avani D Joshi; Satyin Kaura; Marc F Botteman
Journal:  Pharmacoeconomics       Date:  2012-05       Impact factor: 4.981

Review 2.  Anti-cancer actions of denosumab.

Authors:  Jameel Iqbal; Li Sun; Jeffrey I Mechanick; Mone Zaidi
Journal:  Curr Osteoporos Rep       Date:  2011-12       Impact factor: 5.096

Review 3.  Interpreting results from oncology clinical trials: a comparison of denosumab to zoledronic acid for the prevention of skeletal-related events in cancer patients.

Authors:  George Dranitsaris; Eleftheria Hatzimichael
Journal:  Support Care Cancer       Date:  2012-04-27       Impact factor: 3.603

4.  Use of Bone Resorption Inhibitors in Metastatic Castration-Resistant Prostate Cancer-20 Years Later, and the Answer Is Still Yes.

Authors:  Samuel U Takvorian; Naomi B Haas
Journal:  JAMA Netw Open       Date:  2021-07-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.